Abstract
The prognosis of high-grade glioma is poor despite of advanced neurosurgery, radio-and chemotherapy. Dendritic cell (DC)-based immunotherapy has emerged as a promising and feasible treatment approach because of it's high degree of selectivity and the ability to induce a memory response. In our research group we are investigating the efficacy of vaccinating both primary (HGG-2006 trial) and relapsed HGG patients (HGG-IMMUNO-2003 trial) with DC pulsed with autologous whole tumor lysate. Both trials showed a better overall survival compared to historical controls. Currently we are running a placebo-controlled randomized phase IIb clinical trial (HGG-2010) in primary HGG patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
